Do antibody responses to the influenza vaccine persist year-round in the elderly? A systematic review and meta-analysis

Vaccine

Volumn 35, Issue 2, 2017, Pages 212-221

  Young, Barnaby ^a   Zhao, Xiahong ^b   Cook, Alex R ^b,c   Parry, Christopher M ^d,e   Wilder Smith, Annelies ^a,f   I Cheng, Mark Chen ^a,b  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c YALE NUS COLLEGE   (Singapore)

^d NAGASAKI UNIVERSITY   (Japan)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f LEE KONG CHIAN SCHOOL OF MEDICINE   (Singapore)

Author keywords

Elderly; Influenza; Seasonal; Seroprotection; Tropics; Vaccine

Indexed keywords

INFLUENZA VACCINE; VIRUS ANTIBODY;

ANTIBODY RESPONSE; BAYESIAN LEARNING; COCHRANE LIBRARY; COHORT ANALYSIS; EMBASE; HEMAGGLUTINATION INHIBITION; HUMAN; INFLUENZA VACCINATION; MEDLINE; META ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEASONAL INFLUENZA; SEROCONVERSION; SEROTYPE; SYSTEMATIC REVIEW; AGED; ANTIBODY PRODUCTION; BLOOD; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; ORTHOMYXOVIRIDAE; TIME FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; ANTIBODY FORMATION; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA VACCINES; ORTHOMYXOVIRIDAE; TIME FACTORS;

EID: 85007012346     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.11.013     Document Type: Review

References (67)

1. [1] Nair, H., Brooks, W.A., Katz, M., Roca, A., Berkley, J.A., Madhi, S.A., et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet Lond Engl 378 (2011), 1917–1930, 10.1016/S0140-6736(11)61051-9.
2. [2] Thompson, W.W., Comanor, L., Shay, D.K., Epidemiology of seasonal influenza: use of surveillance data and statistical models to estimate the burden of disease. J Infect Dis 194:Suppl. 2 (2006), S82–S91, 10.1086/507558.
3. [3] Jefferson, T., Di Pietrantonj, C., Al-Ansary, L.A., Ferroni, E., Thorning, S., Thomas, R.E., Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev, 2010, CD004876, 10.1002/14651858.CD004876.pub.
4. [4] Song, J.Y., Cheong, H.J., Hwang, I.S., Choi, W.S., Jo, Y.M., Park, D.W., et al. Long-term immunogenicity of influenza vaccine among the elderly: risk factors for poor immune response and persistence. Vaccine 28 (2010), 3929–3935, 10.1016/j.vaccine.2010.03.067.
5. [5] Ohmit, S.E., Petrie, J.G., Cross, R.T., Johnson, E., Monto, A.S., Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis 204 (2011), 1879–1885, 10.1093/infdis/jir661.
6. [6] Brandenburg, B., Koudstaal, W., Goudsmit, J., Klaren, V., Tang, C., Bujny, M.V., et al. Mechanisms of hemagglutinin targeted influenza virus neutralization. PLoS One, 8, 2013, e80034, 10.1371/journal.pone.0080034.
7. [7] Wijnans, L., Voordouw, B., A review of the changes to the licensing of influenza vaccines in Europe. Influenza Other Respir Viruses 10 (2016), 2–8, 10.1111/irv.12351.
8. [8] Skowronski, D.M., Tweed, S.A., De Serres, G., Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant?. J Infect Dis 197 (2008), 490–502, 10.1086/524146.
9. [9] Sullivan, S.G., Komadina, N., Grant, K., Jelley, L., Papadakis, G., Kelly, H., Influenza vaccine effectiveness during the 2012 influenza season in Victoria, Australia: influences of waning immunity and vaccine match. J Med Virol 86 (2014), 1017–1025, 10.1002/jmv.23847.
10. [10] Castilla, J., Martínez-Baz, I., Martínez-Artola, V., Reina, G., Pozo, F., García Cenoz, M., et al. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull, 18, 2013.
11. [11] Pebody, R.G., Andrews, N., McMenamin, J., Durnall, H., Ellis, J., Thompson, C.I., et al. Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull, 18, 2013.
12. [12] Hsu, J.P., Zhao, X., Chen, M.I.-C., Cook, A.R., Lee, V., Lim, W.Y., et al. Rate of decline of antibody titers to pandemic influenza A (H1N1-2009) by hemagglutination inhibition and virus microneutralization assays in a cohort of seroconverting adults in Singapore. BMC Infect Dis, 14, 2014, 414, 10.1186/1471-2334-14-414.
13. [13] Bloom-Feshbach, K., Alonso, W.J., Charu, V., Tamerius, J., Simonsen, L., Miller, M.A., et al. Latitudinal variations in seasonal activity of influenza and respiratory syncytial virus (RSV): a global comparative review. PLoS One, 8, 2013, e54445, 10.1371/journal.pone.0054445.
14. [14] Azziz Baumgartner, E., Dao, C.N., Nasreen, S., Bhuiyan, M.U., Mah-E-Muneer, S., Al Mamun, A., et al. Seasonality, timing, and climate drivers of influenza activity worldwide. J Infect Dis 206 (2012), 838–846, 10.1093/infdis/jis467.
15. [15] Yang, L., Ma, S., Chen, P.Y., He, J.F., Chan, K.P., Chow, A., et al. Influenza associated mortality in the subtropics and tropics: results from three Asian cities. Vaccine 29 (2011), 8909–8914, 10.1016/j.vaccine.2011.09.071.
16. [16] Saha, S., Chadha, M., Al Mamun, A., Rahman, M., Sturm-Ramirez, K., Chittaganpitch, M., et al. Influenza seasonality and vaccination timing in tropical and subtropical areas of southern and south-eastern Asia. Bull World Health Organ 92 (2014), 318–330, 10.2471/BLT.13.124412.
17. [17] Hirve, S., Newman, L.P., Paget, J., Azziz-Baumgartner, E., Fitzner, J., Bhat, N., et al. Influenza seasonality in the tropics and subtropics - when to vaccinate?. PLoS One, 11, 2016, e0153003, 10.1371/journal.pone.0153003.
18. [18] The duration of serological protection against seasonal influenza vaccination in the elderly: a systematic review n.d. http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015023847 [accessed March 30, 2016].
19. [19] Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., Gøtzsche, P.C., Ioannidis, J.P.A., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med, 6, 2009, e1000100, 10.1371/journal.pmed.1000100.
20. [20] Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines n.d. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091985.pdf [accessed April 6, 2016].
21. [21] Hannoun, C., The evolving history of influenza viruses and influenza vaccines. Expert Rev Vaccines 12 (2013), 1085–1094, 10.1586/14760584.2013.824709.
22. [22] Anonymous. Review authors|Cochrane Public Health n.d. http://ph.cochrane.org/review-authors [accessed April 29, 2016].
23. [23] Guyatt, G.H., Oxman, A.D., Vist, G.E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336 (2008), 924–926, 10.1136/bmj.39489.470347.AD.
24. [24] Minutello, M., Senatore, F., Cecchinelli, G., Bianchi, M., Andreani, T., Podda, A., et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 17 (1999), 99–104.
25. [25] Van Hoecke, C., Prikazsky, V., Utö, I., Menschikowski, C., Immunogenicity of an inactivated split influenza vaccine in institutionalized elderly patients. Gerontology 42 (1996), 190–198.
26. [26] Buxton, J.A., Skowronski, D.M., Ng, H., Marion, S.A., Li, Y., King, A., et al. Influenza revaccination of elderly travelers: antibody response to single influenza vaccination and revaccination at 12 weeks. J Infect Dis 184 (2001), 188–191, 10.1086/322013.
27. [27] Iorio, A.M., Camilloni, B., Basileo, M., Neri, M., Lepri, E., Spighi, M., Effects of repeated annual influenza vaccination on antibody responses against unchanged vaccine antigens in elderly frail institutionalized volunteers. Gerontology 53 (2007), 411–418, 10.1159/000110579.
28. [28] Ben-Yehuda, A., Joseph, A., Barenholz, Y., Zeira, E., Even-Chen, S., Louria-Hayon, I., et al. Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents. Vaccine 21 (2003), 3169–3178.
29. [29] GSK Clinical Study Register - study 104886 n.d. http://www.gsk-clinicalstudyregister.com/study/104886#ps [accessed March 20, 2016].
30. [30] Study to evaluate reactogenicity and immunogenicity of revaccination with adjuvanted influenza vaccine in elderly - full text view – ClinicalTrials.gov n.d. https://clinicaltrials.gov/ct2/show/NCT00386113 [accessed March 20, 2016].
31. [31] GSK Clinical Study Register - study 104888 n.d. http://www.gsk-clinicalstudyregister.com/study/104888#rs [accessed March 20, 2016].
32. [32] Demonstrate the superiority of the immune response of adjuvanted influenza vaccine induced in an adult population - full text view – ClinicalTrials.gov n.d. https://clinicaltrials.gov/ct2/show/NCT00377585 [accessed March 20, 2016].
33. [33] Rümke, H.C., Richardus, J.H., Rombo, L., Pauksens, K., Plaßmann, G., Durand, C., et al. Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial. BMC Infect Dis, 13, 2013, 348, 10.1186/1471-2334-13-348.
34. [34] Immunogenicity and safety study to evaluate different formulations of GSK biologicals’ influenza vaccine GSK576389A - full text view – ClinicalTrials.gov n.d. https://clinicaltrials.gov/ct2/show/NCT00540592 [accessed March 20, 2016].
35. [35] Couch, R.B., Bayas, J.M., Caso, C., Mbawuike, I.N., López, C.N., Claeys, C., et al. Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older. BMC Infect Dis, 14, 2014, 425, 10.1186/1471-2334-14-425.
36. [36] Clinical study of the immunogenicity of GSK biologicals’ influenza vaccine GSK2186877A in people aged 65 years or older - full text view – ClinicalTrials.gov n.d. https://clinicaltrials.gov/ct2/show/NCT00765076 [accessed March 20, 2016].
37. [37] McElhaney, J.E., Beran, J., Devaster, J.-M., Esen, M., Launay, O., Leroux-Roels, G., et al. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis 13 (2013), 485–496, 10.1016/S1473-3099(13)70046-X.
38. [38] GSK Clinical Study Register - study 106372 n.d. http://www.gsk-clinicalstudyregister.com/study/106372#ps [accessed March 26, 2016].
39. [39] Trial to evaluate the efficacy of GSK biologicals’ influenza vaccine GSK2186877A in adults 65 year of age and older - study results – ClinicalTrials.gov n.d. https://clinicaltrials.gov/show/NCT00753272 [accessed March 26, 2016].
40. [40] Song, J.Y., Cheong, H.J., Noh, J.Y., Seo, Y.B., Choi, W.S., Cho, G.J., et al. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine. J Med Virol 85 (2013), 1591–1597, 10.1002/jmv.23630.
41. [41] Tinoco, J.C., Pavia-Ruz, N., Cruz-Valdez, A., Aranza Doniz, C., Chandrasekaran, V., Dewé, W., et al. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ⩾18 years: a phase III, randomized trial. Vaccine 32 (2014), 1480–1487, 10.1016/j.vaccine.2014.01.022.
42. [42] A study to evaluate the safety and immunogenicity of GSK biologicals’ seasonal influenza vaccine in adults - study results - ClinicalTrials.gov n.d. https://clinicaltrials.gov/show/NCT01196975 [accessed March 26, 2016].
43. [43] Frey, S.E., Reyes, M.R.A.-D.L., Reynales, H., Bermal, N.N., Nicolay, U., Narasimhan, V., et al. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine 32 (2014), 5027–5034, 10.1016/j.vaccine.2014.07.013.
44. [44] Scheifele, D.W., McNeil, S.A., Ward, B.J., Dionne, M., Cooper, C., Coleman, B., et al. Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: results of a randomized, controlled comparison. Hum Vaccines Immunother 9 (2013), 2460–2473.
45. [45] Saiki, I., Koizumi, K., Goto, H., Inujima, A., Namiki, T., Raimura, M., et al. The long-term effects of a kampo medicine, juzentaihoto, on maintenance of antibody titer in elderly people after influenza vaccination. Evid-Based Complement Altern Med ECAM, 2013, 2013, 568074, 10.1155/2013/568074.
46. [46] Seo, Y.B., Choi, W.S., Lee, J., Song, J.Y., Cheong, H.J., Kim, W.J., Comparison of the immunogenicity and safety of the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines in the elderly. Clin Vaccine Immunol CVI 21 (2014), 989–996, 10.1128/CVI.00615-13.
47. [47] Nace, D.A., Lin, C.J., Ross, T.M., Saracco, S., Churilla, R.M., Zimmerman, R.K., Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities. J Infect Dis 211 (2015), 1915–1924, 10.1093/infdis/jiu622.
48. [48] Chan, T.-C., Hung, I.F.-N., Chan, K.-H., Li, C.P.-Y., Li, P.T.-W., Luk, J.K.-H., et al. Immunogenicity and safety of intradermal trivalent influenza vaccination in nursing home older adults: a randomized controlled trial. J Am Med Dir Assoc 15:607 (2014), e5–e12, 10.1016/j.jamda.2014.05.002.
49. [49] DiazGranados, C.A., Dunning, A.J., Robertson, C.A., Talbot, H.K., Landolfi, V., Greenberg, D.P., Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty. Vaccine 33 (2015), 4565–4571, 10.1016/j.vaccine.2015.07.003.
50. [50] Tsai, T.F., Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults. Infect Chemother 45 (2013), 159–174, 10.3947/ic.2013.45.2.159.
51. [51] DiazGranados, C.A., Dunning, A.J., Kimmel, M., Kirby, D., Treanor, J., Collins, A., et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 371 (2014), 635–645, 10.1056/NEJMoa1315727.
52. [52] Dunning, A.J., DiazGranados, C.A., Voloshen, T., Hu, B., Landolfi, V.A., Talbot, H.K., Correlates of protection against influenza in the elderly: results from an influenza vaccine efficacy trial. Clin Vaccine Immunol CVI 23 (2016), 228–235, 10.1128/CVI.00604-15.
53. [53] Zhao, X., Fang, V.J., Ohmit, S.E., Monto, A.S., Cook, A.R., Cowling, B.J., Quantifying protection against influenza virus infection measured by hemagglutination-inhibition assays in vaccine trials. Epidemiol Camb Mass 27 (2016), 143–151, 10.1097/EDE.0000000000000402.
54. [54] Coudeville, L., Bailleux, F., Riche, B., Megas, F., Andre, P., Ecochard, R., Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol, 10, 2010, 18, 10.1186/1471-2288-10-18.
55. [55] Cheng, L.-W., Huang, S.-W., Huang, L.-M., Chang, L.-Y., Shao, P.-L., Kiang, D., et al. Comparison of neutralizing and hemagglutination-inhibiting antibody responses for evaluating the seasonal influenza vaccine. J Virol Methods 182 (2012), 43–49, 10.1016/j.jviromet.2012.03.004.
56. [56] Verschoor, C.P., Singh, P., Russell, M.L., Bowdish, D.M.E., Brewer, A., Cyr, L., et al. Microneutralization assay titres correlate with protection against seasonal influenza H1N1 and H3N2 in children. PLoS One, 10, 2015, e0131531, 10.1371/journal.pone.0131531.
57. [57] Li, C.K., Rappuoli, R., Xu, X.-N., Correlates of protection against influenza infection in humans–on the path to a universal vaccine?. Curr Opin Immunol 25 (2013), 470–476, 10.1016/j.coi.2013.07.005.
58. [58] McElhaney, J.E., Xie, D., Hager, W.D., Barry, M.B., Wang, Y., Kleppinger, A., et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol Baltim Md 2006:176 (1950), 6333–6339.
59. [59] Ohmit, S.E., Petrie, J.G., Malosh, R.E., Fry, A.M., Thompson, M.G., Monto, A.S., Influenza vaccine effectiveness in households with children during the 2012–2013 season: assessments of prior vaccination and serologic susceptibility. J Infect Dis 211 (2015), 1519–1528, 10.1093/infdis/jiu650.
60. [60] Beyer, W.E., Palache, A.M., Sprenger, M.J., Hendriksen, E., Tukker, J.J., Darioli, R., et al. Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults. Vaccine 14 (1996), 1331–1339.
61. [61] Nath, K.D., Burel, J.G., Shankar, V., Pritchard, A.L., Towers, M., Looke, D., et al. Clinical factors associated with the humoral immune response to influenza vaccination in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 9 (2014), 51–56, 10.2147/COPD.S53590.
62. [62] Sheridan, P.A., Paich, H.A., Handy, J., Karlsson, E.A., Schultz-Cherry, S., Hudgens, M., et al. The antibody response to influenza vaccination is not impaired in type 2 diabetics. Vaccine 33 (2015), 3306–3313, 10.1016/j.vaccine.2015.05.043.
63. [63] Gross, P.A., Quinnan, G.V., Weksler, M.E., Setia, U., Douglas, R.G., Relation of chronic disease and immune response to influenza vaccine in the elderly. Vaccine 7 (1989), 303–308.
64. [64] Talbot, H.K., Coleman, L.A., Zhu, Y., Spencer, S., Thompson, M., Cheng, P.-Y., et al. Factors associated with maintenance of antibody responses to influenza vaccine in older, community-dwelling adults. BMC Infect Dis, 15, 2015, 195, 10.1186/s12879-015-0926-8.
65. [65] Goronzy, J.J., Weyand, C.M., Understanding immunosenescence to improve responses to vaccines. Nat Immunol 14 (2013), 428–436, 10.1038/ni.2588.
66. [66] Baylis, D., Bartlett, D.B., Patel, H.P., Roberts, H.C., Understanding how we age: insights into inflammaging. Longev Heal, 2, 2013, 8, 10.1186/2046-2395-2-8.
67. [67] Frasca, D., Diaz, A., Romero, M., Landin, A.M., Blomberg, B.B., High TNF-α levels in resting B cells negatively correlate with their response. Exp Gerontol 54 (2014), 116–122, 10.1016/j.exger.2014.01.004.